(Q36837124)

16 August 2017

1 reference

title

BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma (English)

1 reference

16 August 2017

1 reference

Christopher R Flowers

series ordinal

1

1 reference

16 August 2017

publication date

1 June 2007

1 reference

Expert Review of Vaccines

16 August 2017

published in

1 reference

16 August 2017

volume

6

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

307-317

1 reference

New treatment options have changed the survival of patients with follicular lymphoma

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

Improved survival of follicular lymphoma patients in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

Current advances, problems and prospects for vaccine-based immunotherapy in follicular non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

Myeloma proteins as tumor-specific transplantation antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.307

21 January 2018

Identifiers

DOI

10.1586/14760584.6.3.307

1 reference

16 August 2017

1 reference